A comparison of vaginal misoprostol versus vaginal misoprostol and nitric oxide donor for termination of pregnancy at 13 to 29 weeks. A prospective randomised trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN44341343

Enrollment

Registered

2002-12-16

Start date

2002-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstetrics and gynaecology Pregnancy and Childbirth Medical abortion

Interventions

After inclusion, patients will be randomised in two groups: First Group (Risordan®): Misoprostol (200 µg) will be administered vaginally every 12 h. In addition, 20 mg isosorbide dinitrate Risordan® w

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. All patients requiring a termination of pregnancy between 13 and 29 weeks of gestation 2. No pregnancy induced hypertension 3. No pre-eclampsia 4. No vaginal bleeding 5. Cervix dilated less then 2 cm 6. No vaginal bleeding 7. At admission blood pressure: systolic >120 mmHg; diastolic >80 mmHg

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration.	—

Secondary

Measure	Time frame
Not provided at time of registration.	—

Countries

Tunisia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026